NCT01123941已完成1 期
A Phase I, Randomized, Single-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Number of Subjects Reporting Serious Adverse Events (SAEs)
研究概览
简要总结
This trial is aimed to evaluate the safety and immunogenicity profiles of a new Vi-CRM197 conjugate vaccine against S. Typhi in healthy human adults in comparison with the currently licensed Vi polysaccharide vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males and females of age ≥18 to ≤40 years.
- •Individuals who, after the nature of the study has been explained to them, have given written consent according to local regulatory requirements.
- •Individuals in good health as determined by the outcome of medical history, physical examination, hematological / hematochemical blood tests and urinalysis and clinical judgment of the investigator.
- •If women, a negative pregnancy test and willingness to use birth control measures for the entire study duration
排除标准
- •Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.
- •Individuals with any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome.
- •Individuals who are not able to understand and to follow all required study procedures for the whole period of the study.
- •Individuals with history of any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
- •Individuals with known or suspected HIV infection or HIV related disease, with history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system, or under immunosuppressive therapy including use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids within the previous 30 days, or were in chemotherapy treatment within the past 6 months.
- •Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
- •Individuals with any serious chronic or progressive disease according to judgment of the investigator.
- •Individuals who have any malignancy or lymphoproliferative disorder.
- •Individuals with history of allergy to vaccine components.
- •Individuals participating in any clinical trial with another investigational product 30 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study.
- •Individuals who have previously received any vaccines against typhoid fever.
- •Individuals who received any other vaccines within 4 weeks prior to enrollment in this study or who are planning to receive any vaccine within 4 weeks from the study vaccine.
- •Individuals who have received blood, blood products and/or plasma derivatives including parenteral immunoglobulin preparations in the past 12 weeks.
- •Individuals with body temperature > 38.0 degrees Celsius within 3 days of intended study immunization.
- •BMI > 35 kg/m
- •Individuals with history of substance or alcohol abuse within the past 2 years.
- •Women who are pregnant or breast-feeding or of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study.
- •Females with history of stillbirth, neonatal loss, or previous infant with anomaly.
- •Individuals who have a previously ascertained or suspected disease caused by S. Typhi.
- •Individuals who have had household contact with/and or intimate exposure to an individual with laboratory confirmed S. Typhi.
结局指标
主要结局
Number of Subjects Reporting Serious Adverse Events (SAEs)
时间窗: During the 6-month period after vaccination
Number of Subjects Reporting Any Post Immunization Reactions
时间窗: During the 7-day period after vaccination
Solicited reactions collected during the 7-day period after vaccination are pain, erythema, induration, chills, malaise, myalgia, headache, arthralgia and fatigue.
Number of Subjects Reporting Adverse Events
时间窗: During the 28-day period after vaccination
次要结局
- Anti-Vi ELISA Geometric Mean Concentration (GMC)(At 28 days after vaccination)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and InfantsTyphoid FeverNCT01229176Novartis200
已完成
2 期
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and InfantsTyphoid FeverNCT01437267Novartis120
已完成
1 期
Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent VaccineCondylomata AcuminataNCT02405520Jun Zhang145
进行中（未招募）
2 期
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and OlderShinglesHerpes ZosterNCT05304351Curevo Inc1,516
已完成
2 期
Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and AdolescentsInfluenzaNCT00645411Novartis3,604